Abstract

Two clinical results of peripheral blood stem cell support are commonly considered: (1) the effect on hematopoietic recovery and (2) the effect on the underlying malignancy. The dynamics of hematopoietic recovery after autoiogous bone marrow transplantation and after autologous peripheral blood stem cell transplantation in a clinical setting are similar if no exogenous cytokines are administered and the peripheral stem ceils are collected while their numbers are not deliberately increased (mobilised). If mobilized peripheral stem cells are transplanted, hematopoietic recovery is accelerated. In some circumstances, patients who receive peripheral stem cell transplantation may experience an improved progression-free survival after high-dose therapy when compared with similar patients who receive autologous bone marrow transplantation. Explanations for such a survival advantage might include (1) a lower likelihood of occult tumor cells capable of restoring disease in peripheral stem cell autograft products than in bone marrow harvests, (2) a greater number of cytotoxic effector cells capable of destroying occult tumor ceils in the peripheral stem cell collections than in bone marrow harvests, and (3) a different and advantageous pattern of immunologic recovery following autologous peripheral stem cell transplant compared to autologous bone marrow transplant.

Original languageEnglish (US)
Pages (from-to)43-46
Number of pages4
JournalMedical Oncology
Volume11
Issue number2
DOIs
StatePublished - Jun 1 1994

Fingerprint

Peripheral Blood Stem Cell Transplantation
Bone Marrow
Bone Marrow Transplantation
Transplants
Neoplasms
Autologous Transplantation
Autografts
Disease-Free Survival
Peripheral Blood Stem Cells
Cytokines
Survival
Therapeutics

Keywords

  • Peripheral blood stem cell support
  • bone marrow transplantation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinical outcome of peripheral blood stem cell support. / Kessinger, Anne; Armitage, James; Bierman, Philip; Bishop, Michael; Joshi, Shantaram; Reed, Elizabeth; Sharp, Graham; Talmadge, James; Vose, Julie.

In: Medical Oncology, Vol. 11, No. 2, 01.06.1994, p. 43-46.

Research output: Contribution to journalArticle

@article{b368a80191c14cfbac711e46775c2cf0,
title = "Clinical outcome of peripheral blood stem cell support",
abstract = "Two clinical results of peripheral blood stem cell support are commonly considered: (1) the effect on hematopoietic recovery and (2) the effect on the underlying malignancy. The dynamics of hematopoietic recovery after autoiogous bone marrow transplantation and after autologous peripheral blood stem cell transplantation in a clinical setting are similar if no exogenous cytokines are administered and the peripheral stem ceils are collected while their numbers are not deliberately increased (mobilised). If mobilized peripheral stem cells are transplanted, hematopoietic recovery is accelerated. In some circumstances, patients who receive peripheral stem cell transplantation may experience an improved progression-free survival after high-dose therapy when compared with similar patients who receive autologous bone marrow transplantation. Explanations for such a survival advantage might include (1) a lower likelihood of occult tumor cells capable of restoring disease in peripheral stem cell autograft products than in bone marrow harvests, (2) a greater number of cytotoxic effector cells capable of destroying occult tumor ceils in the peripheral stem cell collections than in bone marrow harvests, and (3) a different and advantageous pattern of immunologic recovery following autologous peripheral stem cell transplant compared to autologous bone marrow transplant.",
keywords = "Peripheral blood stem cell support, bone marrow transplantation",
author = "Anne Kessinger and James Armitage and Philip Bierman and Michael Bishop and Shantaram Joshi and Elizabeth Reed and Graham Sharp and James Talmadge and Julie Vose",
year = "1994",
month = "6",
day = "1",
doi = "10.1007/BF02988829",
language = "English (US)",
volume = "11",
pages = "43--46",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Clinical outcome of peripheral blood stem cell support

AU - Kessinger, Anne

AU - Armitage, James

AU - Bierman, Philip

AU - Bishop, Michael

AU - Joshi, Shantaram

AU - Reed, Elizabeth

AU - Sharp, Graham

AU - Talmadge, James

AU - Vose, Julie

PY - 1994/6/1

Y1 - 1994/6/1

N2 - Two clinical results of peripheral blood stem cell support are commonly considered: (1) the effect on hematopoietic recovery and (2) the effect on the underlying malignancy. The dynamics of hematopoietic recovery after autoiogous bone marrow transplantation and after autologous peripheral blood stem cell transplantation in a clinical setting are similar if no exogenous cytokines are administered and the peripheral stem ceils are collected while their numbers are not deliberately increased (mobilised). If mobilized peripheral stem cells are transplanted, hematopoietic recovery is accelerated. In some circumstances, patients who receive peripheral stem cell transplantation may experience an improved progression-free survival after high-dose therapy when compared with similar patients who receive autologous bone marrow transplantation. Explanations for such a survival advantage might include (1) a lower likelihood of occult tumor cells capable of restoring disease in peripheral stem cell autograft products than in bone marrow harvests, (2) a greater number of cytotoxic effector cells capable of destroying occult tumor ceils in the peripheral stem cell collections than in bone marrow harvests, and (3) a different and advantageous pattern of immunologic recovery following autologous peripheral stem cell transplant compared to autologous bone marrow transplant.

AB - Two clinical results of peripheral blood stem cell support are commonly considered: (1) the effect on hematopoietic recovery and (2) the effect on the underlying malignancy. The dynamics of hematopoietic recovery after autoiogous bone marrow transplantation and after autologous peripheral blood stem cell transplantation in a clinical setting are similar if no exogenous cytokines are administered and the peripheral stem ceils are collected while their numbers are not deliberately increased (mobilised). If mobilized peripheral stem cells are transplanted, hematopoietic recovery is accelerated. In some circumstances, patients who receive peripheral stem cell transplantation may experience an improved progression-free survival after high-dose therapy when compared with similar patients who receive autologous bone marrow transplantation. Explanations for such a survival advantage might include (1) a lower likelihood of occult tumor cells capable of restoring disease in peripheral stem cell autograft products than in bone marrow harvests, (2) a greater number of cytotoxic effector cells capable of destroying occult tumor ceils in the peripheral stem cell collections than in bone marrow harvests, and (3) a different and advantageous pattern of immunologic recovery following autologous peripheral stem cell transplant compared to autologous bone marrow transplant.

KW - Peripheral blood stem cell support

KW - bone marrow transplantation

UR - http://www.scopus.com/inward/record.url?scp=0028072671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028072671&partnerID=8YFLogxK

U2 - 10.1007/BF02988829

DO - 10.1007/BF02988829

M3 - Article

C2 - 7850263

AN - SCOPUS:0028072671

VL - 11

SP - 43

EP - 46

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 1357-0560

IS - 2

ER -